N-AVD Yields High Progression-Free Survival in Teens With Hodgkin Lymphoma

THURSDAY, Jan. 22, 2026-- For adolescent patients with newly diagnosed advanced-stage (AS) classic Hodgkin lymphoma (cHL), nivolumab, doxorubicin, vinblastine, and dacarbazine (N-AVD) yields high three-year progression-free survival (PFS) with...